Effects of multiple sclerosis disease-modifying therapies on employment measures using patient-reported data
Jing Chen, Bruce V Taylor, Leigh Blizzard, Steve Simpson, Andrew J Palmer, Ingrid AF van der Mei
Journal of Neurology Neurosurgery & Psychiatry | BMJ PUBLISHING GROUP | Published : 2018
BACKGROUND: The direct comparative evidence on treatment effects of available multiple sclerosis (MS) disease-modifying therapies (DMTs) is limited, and few studies have examined the benefits of DMTs on employment outcomes. We compared the effects of DMTs used in the previous 5 years on improving the work attendance, amount of work and work productivity of people with MS. METHODS: The Australian MS Longitudinal Study collected data from participants on DMTs usage from 2010 to 2015 and whether DMTs contributed to changes in employment outcomes. We classified 11 DMTs into three categories based on their clinical efficacy (β-interferons and glatiramer acetate as category 1; teriflunomide and di..View full abstract
This study was supported by the Multiple Sclerosis Research Australia.